uniQure (QURE) Expected to Announce Earnings on Wednesday

uniQure (NASDAQ:QURE) is projected to announce its earnings results before the market opens on Wednesday, February 26th. Analysts expect uniQure to post earnings of ($0.60) per share and revenue of $18.45 million for the quarter.

uniQure Price Performance

uniQure stock opened at $12.84 on Monday. The business’s fifty day moving average is $15.50 and its two-hundred day moving average is $9.66. uniQure has a 52 week low of $3.73 and a 52 week high of $19.18. The company has a debt-to-equity ratio of 0.92, a quick ratio of 6.51 and a current ratio of 6.51. The firm has a market cap of $625.86 million, a P/E ratio of -2.59 and a beta of 0.39.

Insider Activity at uniQure

In related news, CEO Matthew C. Kapusta sold 3,418 shares of uniQure stock in a transaction dated Monday, December 9th. The stock was sold at an average price of $7.63, for a total value of $26,079.34. Following the completion of the sale, the chief executive officer now owns 597,915 shares of the company’s stock, valued at approximately $4,562,091.45. This trade represents a 0.57 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. 4.74% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

A number of research firms have issued reports on QURE. Wells Fargo & Company raised uniQure from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, December 10th. Mizuho increased their price objective on uniQure from $7.00 to $20.00 and gave the company a “neutral” rating in a report on Thursday, December 19th. Stifel Nicolaus upped their price objective on uniQure from $12.00 to $32.00 and gave the company a “buy” rating in a research note on Monday, December 16th. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $24.00 target price on shares of uniQure in a research report on Tuesday, January 21st. Finally, StockNews.com upgraded uniQure to a “sell” rating in a research note on Wednesday, February 5th. One analyst has rated the stock with a sell rating, two have issued a hold rating, six have issued a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $40.00.

About uniQure

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.